TriangleNCT02234115 · CITED IN SOURCE DOCUMENTS
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2019-03-05
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Males aged ≥ 18 years old 2. Males with histologically confirmed carcinoma of the prostate 3. Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy 4. Baseline morning serum testosterone level \> 150 ng/dL performed at Screening Visit 5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2 6. Life expectancy of at least 18 months 7. Laboratory values * Absolute neutrophil count ≥ 1,500 cells/µL * Platelets ≥ 100,000 cells/µL * Hemoglobin ≥ 10 gm/dL * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * AST (SGOT) ≤ 2.5 × ULN * ALT (SGPT) ≤ 2.5 × ULN * Serum creatinine ≤ 1.5 mg/dL * Lipid profile within acceptable range according to investigator's judgment * HgbA1c within acceptable range according to investigator's judgment * Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment * Serum glucose within acceptable range according to investigator's judgement * Urinalysis within normal range according to the investigator's judgment 8. Agree to use male contraceptive methods during study trial 9. Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol 10. All aspects of the protocol explained and written informed consent obtained Exclusion Criteria: * Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study. * Receipt of any vaccination (including influenza) within 4 weeks of Baseline * History of blood donation within 2 months of Baseline * History of anaphylaxis to any LH-RH analogues * Receipt of any LHRH suppressive therapy within 6 months of Baseline * Major surgery, including any prostatic surgery, within 4 weeks of Baseline * History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases. Subjects at risk for spinal cord compression will be excluded. * Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction * History of bilateral orchiectomy, adrenalectomy, or hypophysectomy * History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline * Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator * History of drug and/or alcohol abuse within 6 months of Baseline * Contraindication to leuprolide or an LHRH agonist as indicated on package labeling * Use of 5-alpha reductase inhibitor within the last 6 months of Baseline * History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed * Use of systemic corticosteroids at a dose \>10 mg/d or anti-androgens * Use of any investigational agent within 4 weeks of Baseline * Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for those listed in the permitted Concomitant Treatment section. * Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- MALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
- intervention Names
- Drug: Leuprolide Mesylate
- label
- Leuprolide Mesylate 50mg
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Leuprolide Mesylate 50mg
- description
- Subcutaneous injection of 50mg Leuprolide Mesylate
- name
- Leuprolide Mesylate
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 137
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).
- measure
- Efficacy of Leuprolide Mesylate (LMIS 50mg)
- time Frame
- baseline to 28 days, 28 days to 336 days
- secondary Outcomes
- description
- Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.
- measure
- Number of Participants With Adverse Events (AEs)
- time Frame
- 336 days
Full study description
- brief Summary
- The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
- detailed Description
- This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was established to provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety. If safety is established, the remainder of the subjects will be entered into the clinical study (i.e., Part II). All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-75e174c0fa640c3d2314
- requested nct id
- NCT02234115
- primary nct id
- NCT02234115
- source kind
- fda_spl_label
- source record id
- 4b1ada65-9911-eacf-e063-6394a90af9d9
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 3d5f3785e6ebfd6e0cfed5b8648d979dee88300295e002413192fa319cf4358b
- payload
- application numbers
- NDA211488
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-75e174c0fa640c3d2314
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02234115
- occurrences
- context exact
- 14 CLINICAL STUDIES The efficacy of CAMCEVI was evaluated in an open label, single arm, multinational study FP01C-13-001 ( NCT02234115 ) in patients with advanced prostate carcinoma who have a baseline morning serum testosterone level >150 ng/dL and Eastern Cooperative Oncology Group performan
- end
- 134
- exact text
- NCT02234115
- start
- 123
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/2/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 4b1ada65-9911-eacf-e063-6394a90af9d9
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 42d9bffdaf8029be31fdb81b8295e969435615c3f1fba1d88b7d0ad439450168
- spl effective time
- 20260218
- spl set id
- d7a8761a-d953-413a-e053-2a95a90a60ee
Preserved source evidence · Not medical advice